Immune checkpoint inhibitors have revolutionized cancer therapy, as a monotherapy or in various combinations; the three approved types are anti-PD-1, anti-PDL1, and anti-CTLA4 monoclonal antibodies [15]. This evidence concerns the gene PDCD1 and cancer.